Physician profile
Irene Kim
NPI 1013411602
$2,037.14
in general payments reported to CMS, 2019-2025
19 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.82 · 2022: $507 · 2023: $480 · 2024: $437 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.99 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $347.73 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Intuitive Surgical, INC. | $267.54 | 2022 | |
| Glaxosmithkline, LLC. | $191.73 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $167.55 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $138.22 | 2023-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $85.50 | 2022-2023 | Xarelto |
| Abbvie INC. | $80.03 | 2023-2025 | |
| Inspire Medical Systems, INC. | $78.65 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $71.84 | 2023-2024 | |
| Pfizer INC. | $67.90 | 2022-2024 | |
| Lilly USA, LLC | $37.97 | 2022-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.10 | 2025 | Jardiance |
| Mannkind Corporation | $21.05 | 2023 | Afrezza |
| Idorsia Pharmaceuticals US INC | $18.29 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $17.48 | 2023 | Heplisav-B |
| Sumitomo Pharma America, INC. | $16.56 | 2024 | Gemtesa |
| Tonix Medicines, INC. | $15.90 | 2025 | Tonmya |
| Currax Pharmaceuticals LLC | $14.11 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.